Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports

 
• By Sten Stovall
  
DNA strand
Mologen's immunotherapy focus is on developing DNA-based TLR9 agonists • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D